Top Abstract Purchase Related
Home
>
Node
>
Subnode

Coinfection by human immunodeficiency virus, hepatitis B virus and hepatitis C virus in injecting drug users

Devi, K.S.; Singh, N.B.; Singh, H.L.; Singh, Y.M.

Journal of the Indian Medical Association 107(3): 144; 146-147

2009

ISSN/ISBN: 0019-5847
PMID: 19810379
Document Number: 208531
Detection of hepatitis B surface antigen (HBsAg), anti hepatitis C virus (HCV) antibody and anti human immunodeficiency virus (HIV) antibody was carried out in serum samples from 250 injecting drug users (IDUs) from a deaddiction centre, Shalom, in Churachanpur district, Manipur during the period of August-October, 2002. One hundred and forty-nine (59.6%) IDUs were positive for HIV antibody, 226 (90.4%) were positive for anti HCV antibody and 27 (10.8%) were positive for HBsAg. There was coinfection of HIV, hepatitis B virus (HBV) and HCV in 15 (6%) of the IDUs. The coinfection of HBV and HCV was found in 12 cases (4.8%) and coinfection of HIV and HCV was found in 131 cases (52.4%). HIV and HCV were the highest among the coinfection of IDUs. The IDUs were in sexually active age group with a risk of infection to their sexual partner.

Document emailed within 1 workday
Secure & encrypted payments

Gyarmathy, V.A.; Rácz, J.óz. 2011: Human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) testing among injecting drug users Orvosi Hetilap 152(4): 124-130
Sunthornchart, S.; Linkins, R.W.; Natephisarnwanish, V.; Levine, W.C.; Maneesinthu, K.; Lolekha, R.; Tappero, J.W.; Trirat, N.; Muktier, S.; Chancharastong, P.; Fox, K.; Donchalermpak, S.; Vitek, C.; Supawitkul, S. 2008: Prevalence of hepatitis B, tetanus, hepatitis A, human immunodeficiency virus and feasibility of vaccine delivery among injecting drug users in Bangkok, Thailand, 2003-2005 Addiction 103(10): 1687-1695
Roux, P.; Fugon, L.; Winnock, M.; Salmon-Céron, D.; Lacombe, K.; Sogni, P.; Spire, B.; Dabis, F.ço.; Carrieri, M.P. 2012: Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users Addiction 107(1): 152-159
Chung, D.C.; Ko, Y.C.; Chen, C.J.; Chen, E.R.; Wu, C.C.; Wu, P.S. 1989: Seroepidemiology of hepatitis B virus, hepatitis D virus, and human immunodeficiency virus infections among parenteral drug abusers in southern Taiwan Journal of Medical Virology 28(4): 215-218
Wu, N.; Li, D.; Zhu, B.; Zou, W. 2003: Preliminary research on the co-infection of human immunodeficiency virus and hepatitis virus in intravenous drug users Chinese Medical Journal 116(9): 1318-1320
Solomon, S.S.; Celentano, D.D.; Srikrishnan, A.K.; Vasudevan, C.K.; Murugavel, K.G.; Iqbal, S.H.; Anand, S.; Kumar, M.S.; Latkin, C.; Solomon, S.; Mehta, S.H. 2010: Low incidences of human immunodeficiency virus and hepatitis C virus infection and declining risk behaviors in a cohort of injection drug users in Chennai, India American Journal of Epidemiology 172(11): 1259-1267
Berenguer, M.; López-Labrador, F.X. 1999: Coinfection with the hepatitis C virus and human immunodeficiency virus: clinical and biologic implications Medicina Clinica 113(1): 28-35
Barnawal, S.P.; Niraula, S.R.; Agrahari, A.K.; Bista, N.; Jha, N.; Pokharel, P.K. 2014: Human immunodeficiency virus and hepatitis C virus coinfection in Nepal Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology 33(2): 141-145
Sungkanuparph, S.; Vibhagool, A.; Manosuthi, W.; Kiertiburanakul, S.; Atamasirikul, K.; Aumkhyan, A.; Thakkinstian, A. 2004: Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study Journal of the Medical Association of Thailand 87(11): 1349-1354
Calderón, G.M.; González-Velázquez, F.; González-Bonilla, C.R.; Novelo-Garza, B.ár.; Terrazas, J.J.; Martínez-Rodríguez, M.L.; Cortés-Márquez, S.R.; Blanco-Flores, J.P.; Rodríguez-Rodríguez, A.; Del Campo, M.A.; Cortés-Gómez, R.; Mejía-Bocanegra, M.G. 2009: Prevalence and risk factors of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus in multiply transfused recipients in Mexico Transfusion 49(10): 2200-2207
Kazi, A.M.; Shah, S.A.; Jenkins, C.A.; Shepherd, B.E.; Vermund, S.H. 2010: Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan International Journal of Infectious Diseases: Ijid: Official Publication of the International Society for Infectious Diseases 14(Suppl 3): E60-E66
Ruzibakiev, R.; Kato, H.; Ueda, R.; Yuldasheva, N.; Hegay, T.; Avazova, D.; Kurbanov, F.; Zalalieva, M.; Tuichiev, L.; Achundjanov, B.; Mizokami, M. 2001: Risk factors and seroprevalence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection in uzbekistan Intervirology 44(6): 327-332
Kania, D.; Sangaré, L.; Sakandé, J.; Koanda, A.; Nébié, Y.K.; Zerbo, O.; Combasséré, A.W.; Guissou, I.P.; Rouet, F.ço. 2009: A new strategy to improve the cost-effectiveness of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis testing of blood donations in sub-Saharan Africa: a pilot study in Burkina Faso Transfusion 49(10): 2237-2240
Panlilio, A.L.; Shapiro, C.N.; Schable, C.A.; Mendelson, M.H.; Montecalvo, M.A.; Kunches, L.M.; Perry, S.W.; Edwards, J.R.; Srivastava, P.U.; Culver, D.H. 1995: Serosurvey of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among hospital-based surgeons. Serosurvey Study Group Journal of the American College of Surgeons 180(1): 16-24
Pivert, A.; Payan, C.; Lunel, F.; C, E.R.T. A. 2004: Comparaison des cinétiques de l'ARN et de l'antigène de capside du virus de l'hépatite C dans le suivi thérapeutique des patients co-infectés par le virus de l'hépatite C et le virus de l'immunodéficience humaine, traités par bithérapie interféron-ribavirine, dans le cadre du protocole RIBAVIC - Comparison of hepatitis C viral RNA and core antigen kinetics in the therapeutic follow up of hepatitis C virus and human immunodeficiency virus co-infected patients, treated by bitherapy interferon-ribavirin, within the framework of RIBAVIC protocol Pathologie et Biologie 52(9): 522-528
Bassa, A.; Villalonga, C.; Parras, F.; Salvà, F.; Altés, J.; Salas, A. 1989: Infection caused by the human immunodeficiency virus, hepatitis B virus and delta virus in homosexual males Medicina Clinica 93(13): 490-492
Iroezindu, M.O.; Daniyam, C.A.; Agbaji, O.O.; Isa, E.S.; Okeke, E.N.; Imade, G.E. 2013: Prevalence of hepatitis B e antigen among human immunodeficiency virus and hepatitis B virus co-infected patients in Jos, Nigeria Journal of Infection in Developing Countries 7(12): 951-959
Budhachandra, Y.; Ramesh, K.; Sumitra, G. 2007: Personality profile among Human Immunodeficiency Virus (HIV) positives and Acquired Immunodeficiency Syndrome (AIDS) patients of injecting drug users Kathmandu University Medical Journal 5(1): 38-41
Saves, M.; Raffi, F.; Clevenbergh, P.; Marchou, B.; Waldner-Combernoux, A.; Morlat, P.; LeMoing, V.; Riviere, C.; Chene, G.; Leport, C.; The APROCOStudy Group, 2000: Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients Antimicrobial Agents and Chemotherapy 44(12): 3451-3455
Liang, S.H.; Lo, Y.-C.; Lin, H.-H.; Chang, S.-Y.; Chen, M.-Y.; Hsieh, S.-M.; Sheng, W.-H.; Sun, H.-Y.; Hung, C.-C.; Chang, S.-C. 2008: Seroprevalence of viral hepatitis and infectious complications among human immunodeficiency virus-infected injection drug users at a referral hospital Journal of Microbiology Immunology and Infection 41(3): 200-208